# Beone Medicines (ONC) — Earnings

ONC · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/onc/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $2.05 |
| EPS estimate | $1.66 |
| EPS surprise | +23.45% |
| Revenue surprise | +4.95% |
| Revenue | $1.7B |
| Revenue estimate | $1.6B |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1651308/000162828026052878/bgne-20260630.htm) |

BeOne Medicines reported Q2 2026 results on August 5, 2026. Earnings per share were $2.05, beating the $1.66 estimate by 23.45%. Revenue was $1.7 billion against a $1.6 billion consensus, the highest in the table. Compared with Q2 2025, EPS more than doubled from $0.91 and revenue rose about 31% from $1.3 billion.

The table shows a turn from losses to profits. BeOne posted a loss in 13 of the 20 quarters, all before 2025, with annual losses per share of $19.48 in 2022, $8.50 in 2023 and $6.14 in 2024. The one profitable quarter in that stretch was Q3 2023, at $2.01. EPS reached breakeven in Q1 2025 and has been positive since, giving annual EPS of $2.60 for 2025. Revenue grew about eightfold, from $206.4 million in Q3 2021 to $1.7 billion. Results against estimates were uneven, with 11 beats and 9 misses, including a 50.29% miss in Q4 2025.

BeOne reported Q3 between November 4 and November 12 in each of the past five years. That points to early or mid-November 2026 for the next report. It will show whether quarterly revenue stays at or above the latest $1.7 billion.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | $1.66 | $2.05 | 23.45% | $1.6B | $1.7B |
| Q1 2026 | May 6, 2026 | $1.54 | $1.96 | 27.52% | $1.5B | $1.5B |
| Q4 2025 | Feb 26, 2026 | $1.21 | $0.60 | -50.29% | $1.5B | $1.5B |
| Q3 2025 | Nov 6, 2025 | $0.85 | $1.09 | 28.14% | $1.4B | $1.4B |
| Q2 2025 | Aug 6, 2025 | $0.39 | $0.91 | 134.90% | $1.2B | $1.3B |
| Q1 2025 | May 7, 2025 | −$0.57 | $0.00 | 100.00% | $1.1B | $1.1B |
| Q4 2024 | Feb 27, 2025 | −$1.01 | −$1.43 | -41.28% | $1.0B | $1.1B |
| Q3 2024 | Nov 12, 2024 | −$1.11 | −$1.15 | -3.24% | $983.3M | $1.0B |
| Q2 2024 | Aug 7, 2024 | −$2.19 | −$1.15 | 47.47% | $810.3M | $929.2M |
| Q1 2024 | May 8, 2024 | −$3.09 | −$2.41 | 22.11% | $670.1M | $751.7M |
| Q4 2023 | Feb 26, 2024 | −$3.49 | −$3.53 | -1.18% | $637.0M | $634.4M |
| Q3 2023 | Nov 9, 2023 | −$3.38 | $2.01 | 159.38% | $596.8M | $781.3M |
| Q2 2023 | Aug 2, 2023 | −$3.36 | −$3.64 | -8.29% | $501.1M | $595.3M |
| Q1 2023 | May 4, 2023 | −$3.66 | −$3.34 | 8.83% | $444.2M | $447.8M |
| Q4 2022 | Feb 27, 2023 | −$4.64 | −$4.29 | 7.45% | $388.2M | $380.1M |
| Q3 2022 | Nov 9, 2022 | −$3.91 | −$5.39 | -37.88% | $385.7M | $387.6M |
| Q2 2022 | Aug 4, 2022 | −$4.01 | −$5.56 | -38.72% | $313.2M | $341.6M |
| Q1 2022 | May 5, 2022 | −$4.12 | −$4.24 | -2.80% | $260.4M | $306.6M |
| Q4 2021 | Feb 25, 2022 | −$4.97 | −$6.16 | -23.87% | $214.6M | $214.0M |
| Q3 2021 | Nov 4, 2021 | −$4.70 | −$4.46 | 5.11% | $186.3M | $206.4M |

## Frequently Asked Questions

### When did Beone Medicines (ONC) last report earnings?

Beone Medicines last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did ONC beat earnings estimates?

Yes. Beone Medicines reported EPS of $2.05 for Q2 2026 against a $1.66 estimate — a 23.45% beat.

### How much revenue did ONC report last quarter?

Beone Medicines reported $1.7B in revenue for Q2 2026, against a consensus estimate of $1.6B.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).